Alaunos Therapeutics Terminates Material Agreement

TL;DR

Alaunos terminated a key deal, filing 8-K with financial updates.

AI Summary

Alaunos Therapeutics, Inc. announced on October 4, 2024, the termination of a material definitive agreement. The company also reported on its results of operations and financial condition, and filed financial statements and exhibits. This filing follows a period where the company was formerly known as ZIOPHARM ONCOLOGY INC.

Why It Matters

The termination of a material definitive agreement can significantly impact a company's strategic direction and financial future. Investors will be looking for details on the reasons for termination and any potential consequences.

Risk Assessment

Risk Level: medium — Termination of a material agreement introduces uncertainty regarding the company's business operations and financial stability.

Key Players & Entities

• Alaunos Therapeutics, Inc. (company) — Registrant
• ZIOPHARM ONCOLOGY INC (company) — Former company name
• October 4, 2024 (date) — Date of earliest event reported
• October 10, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share TCRT The Nasdaq Stock Mar

Filing Documents

• tcrt-20241004.htm (8-K) — 59KB
• 0000950170-24-113960.txt ( ) — 182KB
• tcrt-20241004.xsd (EX-101.SCH) — 31KB
• tcrt-20241004_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition Alaunos continues to progress and evaluate its internally developed small molecule oral obesity program. The aim of this program is to develop a drug for obesity with a differentiated profile relative to currently marketed and in development oral and injectable products. We believe our small molecule product candidates are distinct in that they do not rely on hormonal manipulation, which is common with many obesity treatments. We have engaged a contract development and manufacturing organization (CMDO) to manufacture active pharmaceutical ingredients for our small molecule product candidates. Reductions in overhead expenditures have extended the Company's cash runway into the first quarter of 2025. We anticipate initiating in vitro testing of our candidates in the fourth quarter 2024. If successful, we plan to conduct an in vivo efficacy study in the first half of 2025, followed by the initiation of nonclinical and IND-enabling activities in 2025. Our ability to execute on this plan is dependent on study results and our ability to raise additional capital or partner these assets. The foregoing descriptions of the A&R License Agreement do not purport to be complete and are qualified in their entirety by the terms and conditions of the full text of the A&R License Agreement, which was previously filed as Exhibit 10.27 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission by the Company on April 1, 2024.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are all statements contained in this Current Report on Form 8-K that are not historical fact, and in some cases can be identified by terms such as: "aim," "anticipate," "believe," "continue," "estimate," "expect," "forecast," "hope," "intend," "may," "plan," "possible," "project," "target," "potential," "will" and other words and terms of similar meaning. These statements are based on management's current beliefs and assumptions and on information currently available to management. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cautions you that these statements are based on a combination of facts and factors currently known by the Company and the Company's projections of the future, about which the Company cannot be certain. Forward-looking statements in this Current Report on Form 8-K include, but are not limited to, statements about: (i) the Company's ability to successfully implement the strategic reprioritization or realize any or all of the anticipated benefits once implemented; (ii) the Company's ability to raise substantial additional capital to continue as a going concern and fund planned operations in the near term and the strategic reprioritization in the longer term; (iii) the Company's ability to successfully consummate any strategic transactions, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions; (iv) estimates regarding the Company'

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alaunos Therapeutics, Inc. Date. October 10, 2024 By: /s/ Melinda Lackey Name: Melinda Lackey Title: Legal and Administration

View Full Filing

View this 8-K filing on SEC EDGAR